Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer

Inclusion Criteria: * Histologically confirmed pancreatic cancer. * Measurable disease. * Absence of ascites or obstructive jaundice. * ECOG Performance Status 0-2. * Adequate liver kidney and bone marrow function. * Written informed consent. Exclusion Criteria: * Chronic diarrheic syndrome. * Uncontrolled brain metastases after radiation. * Liver infiltration over 50%. * Peripheral neuropathy ≥ 2. * No second primary malignancy within the past 5 years, except non-melanomas skin cancer or in situ carcinoma of the cervix. * No active uncontrolled infection. * Active cardiac disease : unstable angina or onset of angina within last 3 months, myocardial infarction within 6 months, congestive heart failure \> class II, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. * Women who are pregnant or lactating.